JAGANI, Zainab,BETTENCOURT, Brian,MILSTEIN, Stuart,TOUD-JARSKA, Ivanka,MCDONALD, Earl,SCHLABACH Jr., Michael,STEGMEIER, Frank P.,WARMUTH, Markus,GAMPA, Kalyani,HUESKEN, Dieter,STUMP, Mark,WEILER, Jan
申请号：
AU2017261481
公开号：
AU2017261481A1
申请日:
2017.11.14
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2017261481A120171130.pdf#####ABSTRACT The present disclosure relates to RNAi agents useful in methods of treating KRASrelated diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.
